Cancer Target Validation Using siRNA Delivery
By Biotechdaily staff writers
Posted on 25 Jul 2003
A collaboration to use small interfering RNA (siRNA) delivery in animal models of disease to validate cancer targets has been announced by Intradigm Corp. (Rockville, MD, USA) and Europroteome AG (Hennigsdorf, Germany). Posted on 25 Jul 2003
Intradigm will apply its siRNA-based disease control validation in animal tumor models for one of Europroteome's cancer targets. The 21-23 base pairs, double-stranded RNA molecule can be utilized to knock down the expression of cancer-causing genes in a sequence-specific manner. Intradigm has developed a portfolio of delivery systems for siRNA duplexes capable of efficient delivery into pathologic tissues, including human xenograft tumor models. Intradigm has applied this technology to successfully validate cancer targets. Europroteome has also identified and validated cancer targets based on its proteomic and human-cell-based studies.
"We are very pleased to enter into this collaboration with Europroteome. We believe it further demonstrates the value of Intradigm's siRNA-based disease control validation technology to add value to Europroteome's important cancer target,” said John Spears, CEO of Intradigm.
Related Links:
Intradigm
Europroteome